JP2703193B2 - Method for resolving a racemic mixture of cis compounds of 2-diphenylmethyl-N-[(2-methoxyphenyl) methyl] -1-azabicyclo [2,2,2] octane-3-amine - Google Patents
Method for resolving a racemic mixture of cis compounds of 2-diphenylmethyl-N-[(2-methoxyphenyl) methyl] -1-azabicyclo [2,2,2] octane-3-amineInfo
- Publication number
- JP2703193B2 JP2703193B2 JP6322355A JP32235594A JP2703193B2 JP 2703193 B2 JP2703193 B2 JP 2703193B2 JP 6322355 A JP6322355 A JP 6322355A JP 32235594 A JP32235594 A JP 32235594A JP 2703193 B2 JP2703193 B2 JP 2703193B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction
- azabicyclo
- formula
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Abstract
Description
【0001】[0001]
【産業上の利用分野及び従来の技術】本発明は、サブス
タンスP活性を有する置換2−ジフェニルメチル−N−
[(2−メトキシフェニル)メチル]−1−アザビシク
ロ[2,2,2]オクタン−3−アミンのシス化合物の
ラセミ混合物の分割方法に関する。該ラセミ化合物は、
中間体であるアザビシクロ[2,2,2]オクタン−3
−イミン類から製造できる。中間体アザビシクロ[2,
2,2]オクタン−3−イミン類はフェニルメチルイミ
ン中間体から製造できる。The present invention relates to a substituted 2-diphenylmethyl-N-substrate having substance P activity.
The present invention relates to a method for resolving a racemic mixture of a cis compound of [(2-methoxyphenyl) methyl] -1-azabicyclo [2,2,2] octane-3-amine. The racemate is
Azabicyclo [2,2,2] octane-3 as an intermediate
-Can be produced from imines. The intermediate azabicyclo [2,
2,2] Octane-3-imines can be prepared from phenylmethylimine intermediates.
【0002】上記ラセミ化合物、それらの製造方法、及
びそれらのサブスタンスP拮抗能力は国際出願公開公報
第WO90/05729号に開示されている。これらの
化合物は過剰なサブスタンスPによって惹起される疾患
の治療に有効である。サブスタンスPはタキキニン系ペ
プチドに属する、天然に産生するウンデカペプチドであ
り、タキキニン系ペプチドは平滑筋組織に対するそれら
の迅速な刺激作用のためにこのように呼ばれる。さらに
詳しくは、サブスタンスPは哺乳動物において産生され
る(本来、腸から単離される)薬理学的活性な神経ペプ
チドであり、特徴的なアミノ酸配列を有する。多くの疾
患の病態生理学にサブスタンスPとその他のタキキニン
が広範囲に関係していることは当該技術分野において詳
細に実証されている。このような疾患の例は精神病、偏
頭痛、リウマチ性関節炎及び潰瘍性大腸炎である。[0002] The above-mentioned racemates, their production methods and their ability to antagonize substance P are disclosed in WO 90/05729. These compounds are effective in treating diseases caused by excess substance P. Substance P is a naturally occurring undecapeptide belonging to the tachykinin-based peptides, and tachykinin-based peptides are so named for their rapid stimulatory effect on smooth muscle tissue. More specifically, substance P is a pharmacologically active neuropeptide produced in mammals (essentially isolated from the intestine) and has a characteristic amino acid sequence. The extensive involvement of substance P and other tachykinins in the pathophysiology of many diseases has been well documented in the art. Examples of such diseases are psychosis, migraine, rheumatoid arthritis and ulcerative colitis.
【0003】[0003]
【発明が解決しようとする課題および課題を解決するた
めの手段】本発明は、式:The problem to be solved by the present invention is as follows:
【化2】 で示されるcis−化合物のラセミ混合物を(−)マン
デル酸と反応させ、式VII 化合物の(−)マンデル酸塩
を精製し、(−)マンデル酸塩を処理し、式VIIの
(−)の化合物を回収することによる前記ラセミ化合物
の分割方法に関する。Embedded image Racemic mixture of the compound - cis shown in (-) is reacted with mandelic acid, of the formula VII the compound (-) was purified mandelate, (-) mandelate processes, of the formula VII - the () The present invention relates to a method for resolving the racemate by recovering the compound.
【0004】式VII の化合物は、以下のようにして製造
できる。The compound of formula VII can be prepared as follows.
【0005】まず、式:First, the equation:
【化3】 で示される化合物と、式:Embedded image And a compound represented by the formula:
【化4】 [式中、AはMgCl、MgBr又はリチウムである]
で示される化合物とを反応させることによって、式:Embedded image Wherein A is MgCl, MgBr or lithium.
By reacting with a compound represented by the formula:
【化5】 で示される化合物を製造する。Embedded image Is produced.
【0006】式IIaの化合物は、式:The compound of formula IIa has the formula:
【化6】 で示される化合物と、式:Embedded image And a compound represented by the formula:
【化7】 で示される化合物とを反応させることによって、式:Embedded image By reacting with a compound represented by the formula:
【化8】 で示される化合物を製造することによって得ることがで
きる。Embedded image Can be obtained by producing the compound represented by
【0007】次に、式:Next, the formula:
【化9】 で示される化合物をさらにトリアセトキシホウ水素化ナ
トリウムと酢酸とによって還元することによって、式:Embedded image Is further reduced with sodium triacetoxyborohydride and acetic acid to give a compound of the formula:
【化10】 で示されるシス化合物のラセミ混合物を製造する。Embedded image To produce a racemic mixture of the cis compounds
【0008】発明の詳細な説明 式IIa化合物と式 IIIa化合物との反応は、式 IIIaの
グリニャール試薬を溶解させることができる反応に不活
性な溶剤中で実施される。適当な溶剤は例えばジ(C1
−C6 )アルキルエーテル又は環状エーテル例えばテト
ラヒドロフランもしくはジオキサンのようなエーテルで
ある。他の適当な溶剤はトルエン、ジメトキシ−エタン
及びグリムである。これらの溶剤の混合物も同様に使用
可能である。反応温度は一般に約0℃から室温までの範
囲である。反応速度を高めるためには、約50℃以上の
高い反応温度も使用可能である。[0008] reaction of the detailed description formula IIa compound of formula IIIa compounds of the invention is carried out in an inert solvent in the reaction, which can dissolve the Grignard reagent of formula IIIa. Suitable solvents are, for example, di (C 1
-C 6) ethers such as alkyl ethers or cyclic ethers such as tetrahydrofuran or dioxane. Other suitable solvents are toluene, dimethoxy-ethane and glyme. Mixtures of these solvents can be used as well. Reaction temperatures generally range from about 0 ° C to room temperature. Higher reaction temperatures of about 50 ° C. or higher can be used to increase the reaction rate.
【0009】式IVa化合物と式Va化合物との反応は、
例えば芳香族炭化水素(例えばトルエン、キシレン又は
ベンゼン)のような、反応に不活性な溶剤中で実施され
る。この反応は一般に室温から反応に不活性な溶剤の還
流温度までの範囲内の温度において実施される。この反
応中には、一般に酸触媒が存在する。このような触媒の
例は例えば樟脳スルホン酸及びp−トルエンスルホン酸
のようなスルホン酸である。The reaction of a compound of formula IVa with a compound of formula Va
The reaction is carried out in a solvent inert to the reaction, for example, an aromatic hydrocarbon (eg, toluene, xylene or benzene). The reaction is generally carried out at a temperature in the range from room temperature to the reflux temperature of the solvent inert to the reaction. During this reaction, an acid catalyst is generally present. Examples of such catalysts are sulfonic acids such as, for example, camphorsulfonic acid and p-toluenesulfonic acid.
【0010】式Ia化合物のトリアセトキシホウ水素化
ナトリウムと酢酸とによる還元は、一般に約5〜約50
℃、通常は約20〜約25℃、例えば室温において実施
される。The reduction of a compound of formula Ia with sodium triacetoxyborohydride and acetic acid is generally from about 5 to about 50.
C., usually at about 20 to about 25C, for example at room temperature.
【0011】式VII 化合物と(−)マンデル酸との反応
は一般に酢酸エチル中で実施される。この後の精製は一
般に、酢酸エチル中で還流温度において(−)マンデル
酸塩をスラリー化することによって実施される。この精
製された塩を強塩基で処理して、式VII の(−)化合物
を回収する。この処理は一般にpH10〜12において
実施される。強塩基の例は例えばアルカリ金属水酸化物
(例えば水酸化カリウム)のような強無機塩基と、例え
ば炭酸カリウムのようなアルカリ金属炭酸塩である。The reaction of the compound of formula VII with (-) mandelic acid is generally carried out in ethyl acetate. Subsequent purification is generally performed by slurrying the (-) mandelic acid salt at reflux in ethyl acetate. The purified salt is treated with a strong base to recover the (-) compound of formula VII. This treatment is generally performed at pH 10-12. Examples of strong bases are strong inorganic bases, such as, for example, alkali metal hydroxides (eg, potassium hydroxide) and alkali metal carbonates, such as, for example, potassium carbonate.
【0012】本発明の最終化合物は、上記国際出願公開
公報第WO90/05729号にさらに詳細に説明され
るように、約5.0mg/日〜約1500mg/日の範
囲内の用量で、経口経路、非経口経路又は局所経路のい
ずれかで投与されることができる。The final compounds of the present invention can be administered by the oral route at doses ranging from about 5.0 mg / day to about 1500 mg / day, as described in further detail in WO 90/05729. Can be administered by either the parenteral or topical route.
【0013】サブスタンスPアンタゴニストとしての本
発明の最終化合物の活性は、ウシ尾組織のサブスタンス
Pの受容体部位におけるサブスタンスPの結合を阻止す
るそれらの能力によって、オートラジオグラフィーによ
ってタキキニン受容体を可視化するために放射性リガン
ドを用いて評価される。ここに述べるキヌクリジン化合
物類のサブスタンスPアンタゴニスト活性はJourn
al of Biological Chemistr
y,258巻,5158頁(1983)に報告される、
M.A.Cascieri等が述べる標準分析方法を用
いて評価される。この方法は本質的に、前記単離ウシ組
織のサブスタンスP受容体部位における放射性標識サブ
スタンスPリガンド量を50%減ずるために必要な個々
の化合物濃度を測定し、それによって各供試化合物の特
徴的IC50を得ることを含む。The activity of the final compounds of the invention as substance P antagonists makes the tachykinin receptor visible by autoradiography, due to their ability to block the binding of substance P at the substance P receptor site in bovine tail tissue. Is evaluated using a radioligand. The substance P antagonist activity of the quinuclidine compounds described herein is determined by Journal.
al of Biological Chemistr
y , vol. 258, p. 5158 (1983),
M. A. It is evaluated using standard analytical methods described by Cascieri et al. This method essentially determines the individual compound concentration required to reduce the amount of radiolabeled substance P ligand at the substance P receptor site of the isolated bovine tissue by 50%, thereby characterizing each test compound. It includes obtaining the IC 50.
【0014】下記実施例によって、本発明を説明する。The following examples illustrate the invention.
【0015】[0015]
【実施例】実施例1 A.N−[(2−メトキシフェニル)メチル]−2−フ
ェニルメチレン−1−アザビシクロ[2,2,2]−オ
クタン−3−イミン メカニカルスターラー、温度計、冷却管、Dean S
tarkトラップを備えた12L三つ口丸底フラスコ
(3nrbf)に、トルエン 5.9L、2−フェニル
メチレン−1−アザビシクロ[2,2,2]−オクタン
−3−イミン 791.8g(3.7モル)、2−メト
キシベンジルアミン 764g(5.6モル、1.5当
量)、及び(+)樟脳スルホン酸 8.8g(0.00
39モル)を装入した。この溶液を還流するまで(11
6℃)加熱し、42時間還流させた。Dean Sta
rkトラップには全体で75mlの水が回収され、反応
が進行していることを示した。標題生成物を含む溶液を
室温に冷却した。EXAMPLES Example 1 A. N-[(2-methoxyphenyl) methyl] -2-f
Phenylmethylene-1-azabicyclo [2,2,2] -o
Cutane-3-imine mechanical stirrer, thermometer, cooling pipe, Dean S
In a 12 L three-neck round bottom flask (3 nrbf) equipped with a trap trap, 5.9 L of toluene, 791.8 g of 2-phenylmethylene-1-azabicyclo [2,2,2] -octane-3-imine (3.7 g). Mol), 764 g (5.6 mol, 1.5 equivalents) of 2-methoxybenzylamine, and 8.8 g (0.00) of (+) camphorsulfonic acid.
39 mol). The solution is refluxed (11
(6 ° C.) and refluxed for 42 hours. Dean Sta
A total of 75 ml of water was collected in the rk trap, indicating that the reaction was in progress. The solution containing the title product was cooled to room temperature.
【0016】単離した場合に、下記NMRデータが得ら
れた: 1H NMR(CDCl3 ):8.05(d,2
H),7.40−6.80(m,9H),4.80
(s,2H),3.80(s,3H),3.25−2.
95(m,5H),1.90−1.70(m,4H)。When isolated, the following NMR data were obtained: 1 H NMR (CDCl 3 ): 8.05 (d, 2)
H), 7.40-6.80 (m, 9H), 4.80.
(S, 2H), 3.80 (s, 3H), 3.25-2.
95 (m, 5H), 1.90-1.70 (m, 4H).
【0017】B.2−(ジフェニルメチル)−N−
[(2−メトキシフェニル)メチル]−1−アザビシク
ロ[2,2,2]−オクタン−3−イミン 5℃の3Mフェニルマグネシウムブロミド/ジエチルエ
ーテル溶液1.8L(5.6モル,1.5当量)を含む
22L三つ口フラスコに、この実施例のパートAで得ら
れた溶液を装入した。このトルエン溶液は、温度を10
℃未満に維持しながら、1.5時間にわたって加えた。
トルエン溶液の約半分を加えた後に、黄褐色スラリーが
得られた。反応を室温に加温しながら12〜18時間攪
拌した。黄褐色スラリーを5℃に冷却し、6.1Lの水
によって徐々に反応を停止させた。停止した反応にCe
lite 500g量を加え、これを30℃に加温し、
30℃において30分間攪拌した。このスラリーをCe
liteに通して濾過し、トルエンによって洗浄した。
層を分離し、水層をトルエン1Lによって洗浄し、有機
層を一緒にし、硫酸マグネシウム500gによって30
分間乾燥させた。このスラリーを濾過し、濾液を濃厚な
油性固体になるまで真空蒸発させた。この濃厚な油性固
体にイソプロパノール(4.5L)を加え、得られたス
ラリーを5℃に冷却し、この温度において1時間顆粒化
させた。固体を濾別し、冷イソプロパノール0.5Lで
洗浄し、50℃において真空蒸発させて、標題化合物4
94.9g(2工程にわたって30.5%)を得た。融
点:154−158℃。 1HNMR(CDCl3 ):
7.45−6.70(m,14H),4.65(d,1
H),4.45(q,2H),4.25(d,2H),
3.80(s,3H),3.15−3.00(m,3
H),2.70−2.35(m,2H),1.85−
1.65(m,4H)。B.2- (diphenylmethyl) -N-
[(2-Methoxyphenyl) methyl] -1-azabizik
B [2,2,2] -Octane-3-imine 3M phenylmagnesium bromide / diethyl ether at 5 ° C
-1.8L (5.6 mol, 1.5 equivalent)
In a 22 L three-necked flask, obtain the sample obtained in Part A of this example.
The solution was charged. This toluene solution has a temperature of 10
The addition was continued over 1.5 hours while maintaining the temperature below ° C.
After adding about half of the toluene solution, a tan slurry is formed.
Obtained. The reaction is stirred for 12-18 hours while warming to room temperature.
Stirred. Cool the tan slurry to 5 ° C. and add 6.1 L of water
Gradually stopped the reaction. Ce added to the stopped reaction
Add 500g of lite and warm it to 30 ° C,
Stirred at 30 ° C. for 30 minutes. This slurry is
Filtered through a lite and washed with toluene.
Separate the layers, wash the aqueous layer with 1 L of toluene,
Combine the layers and add 30 g with 500 g magnesium sulfate.
Dried for minutes. The slurry is filtered and the filtrate is concentrated.
Vacuum evaporated to an oily solid. This thick oily solid
Isopropanol (4.5 L) was added to the body,
Cool the rally to 5 ° C and granulate at this temperature for 1 hour
I let it. The solid is filtered off and 0.5 l of cold isopropanol is added.
Wash and evaporate in vacuo at 50 ° C. to give the title compound 4
94.9 g (30.5% over two steps) were obtained. Fusion
Point: 154-158 ° C.1HNMR (CDClThree ):
7.45-6.70 (m, 14H), 4.65 (d, 1
H), 4.45 (q, 2H), 4.25 (d, 2H),
3.80 (s, 3H), 3.15-3.00 (m, 3
H), 2.70-2.35 (m, 2H), 1.85-
1.65 (m, 4H).
【0018】実施例2 2−ジフェニルメチル−N−[(2−メトキシフェニ
ル)メチル]−1−アザビシクロ[2,2,2]−オク
タン−3−アミン 22L三つ口フラスコに、酢酸10.3Lを装入した後
に、トリアセトキシホウ水素化ナトリウム531.1g
(2.5モル)を15分間にわたって加えた。この溶液
に実施例1Bの標題化合物411.5g(1.0モル)
を20分間にわたって加えた。この添加中に温度は25
℃から30℃に上昇した。反応を周囲温度において4.
5時間攪拌し、次に濃厚な油状物に成るまで濃縮した。
この油状物を塩化メチレン3.1Lと水6.3Lとに分
配した。この混合物のpHを50%水酸化ナトリウム6
45mlによって4.2から8.4に調節した。層を分
離し、水層を塩化メチレン1.4Lによって洗浄し、有
機層を一緒にし、硫酸マグネシウム500gによって3
0分間乾燥させた。このスラリーを濾過し、濾液を油状
物になるまで真空蒸発させた。この油状物をイソプロパ
ノール3.3Lで希釈すると、白色固体の濃厚な沈殿が
生じた。このスラリーを真空下で35℃に加熱して、残
留塩化メチレンを除去し、5℃に冷却し、30分間顆粒
化させた。白色固体を濾過によって単離させ、冷イソプ
ロパノールで洗浄し、45℃において真空乾燥させて、
標題化合物(ラセミ混合物)356gを86.1%収率
で得た。融点は133−135℃であった。[0018]Example 2 2-diphenylmethyl-N-[(2-methoxyphenyl
L) Methyl] -1-azabicyclo [2,2,2] -oct
Tan-3-amine After charging 10.3 L of acetic acid to a 22 L three-necked flask
In addition, sodium triacetoxyborohydride 531.1 g
(2.5 mol) was added over 15 minutes. This solution
To the title compound of Example 1B, 411.5 g (1.0 mol)
Was added over 20 minutes. During this addition, the temperature was 25
C. to 30.degree. 3. Run the reaction at ambient temperature
Stirred for 5 hours, then concentrated to a thick oil.
This oil was separated into 3.1 L of methylene chloride and 6.3 L of water.
Arranged. The pH of this mixture is adjusted to 50% sodium hydroxide 6
Adjusted from 4.2 to 8.4 with 45 ml. Min layer
Separate and wash the aqueous layer with 1.4 L of methylene chloride.
Combine the layers and add 3
Dry for 0 minutes. The slurry is filtered and the filtrate is oily.
Vacuum evaporated to a solid. Isolate this oil
When diluted with 3.3 L of ethanol, a thick precipitate of white solid is formed.
occured. The slurry was heated to 35 ° C. under vacuum and the remaining
Remove the methylene chloride, cool to 5 ° C, and granulate for 30 minutes.
It was made. The white solid is isolated by filtration and the cold isop
Wash with lopanol, vacuum dry at 45 ° C.,
86.1% yield of 356 g of the title compound (racemic mixture)
I got it. The melting point was 133-135 ° C.
【0019】実施例3 (−)−2−ジフェニルメチル−N−[(2−メトキシ
フェニル)メチル]−1−アザビシクロ[2,2,2]
−オクタン−3−アミン メカニカルスターラーと温度計とを装備した22L三つ
口フラスコに、実施例2の標題化合物345g(0.8
4モル)と酢酸エチル10.4Lとを装入した。反応を
25℃において10分間攪拌すると、濁りを帯びた溶液
が生じた。この溶液に(−)マンデル酸127.2g
(0.84モル)を装入し、20−25℃において約4
分間攪拌した後に、白色スラリーが生じた。この反応混
合物をこの温度において2時間攪拌してから、白色固体
を濾過によって単離させ、酢酸エチルによって洗浄し、
風乾させて、マンデル酸塩386g(81.8%)を得
た。この収率は理論収量が236gである目的ジアステ
レオマー塩の31.8%過剰を表す。 Example 3 (-)-2-diphenylmethyl-N-[(2-methoxy
Phenyl) methyl] -1-azabicyclo [2,2,2]
In a 22 L three-necked flask equipped with an octane-3-amine mechanical stirrer and a thermometer, 345 g of the title compound of Example 2 (0.8 g) was added.
4 mol) and 10.4 L of ethyl acetate. The reaction was stirred at 25 ° C. for 10 minutes resulting in a hazy solution. 127.2 g of (-) mandelic acid was added to this solution.
(0.84 mol) and about 4 at 20-25 ° C.
After stirring for minutes, a white slurry formed. The reaction mixture is stirred at this temperature for 2 hours, then the white solid is isolated by filtration, washed with ethyl acetate,
Air dried to give 386 g (81.8%) of the mandelic salt. This yield represents a 31.8% excess of the desired diastereomer salt with a theoretical yield of 236 g.
【0020】この塩を下記方法によって精製した。不純
なマンデル酸塩(386g)を還流酢酸エチル7.7L
中で45分間スラリー化し、1時間にわたって20−2
5℃に冷却し、濾過し、酢酸エチル約1Lで洗浄した。
溶媒で湿ったケーキを還流酢酸エチル5.5L中で45
分間スラリー化し、1時間にわたって20−25℃に冷
却し、濾過し、酢酸エチル約1Lで洗浄した。溶媒で湿
ったケーキを還流酢酸エチル4.0L中で45分間スラ
リー化し、1時間にわたって20−25℃に冷却し、濾
過し、酢酸エチル約1Lで洗浄し、風乾させて、目的ジ
アステレオマー塩199.6g(84.6%収率)を得
た。このマンデル酸塩の比旋光度(specific
rotation)は[α]D =−51.5゜(CH2
Cl2 ,c=0.55)であり、融点は196−198
であった。This salt was purified by the following method. Impurity mandelate (386 g) was added to 7.7 L of refluxing ethyl acetate.
Slurry for 45 minutes in 20-2 for 1 hour.
Cool to 5 ° C., filter and wash with about 1 L of ethyl acetate.
The solvent wet cake was dried in 5.5 L of refluxing ethyl acetate for 45 hours.
Slurried for 1 minute, cooled to 20-25 ° C. for 1 hour, filtered and washed with about 1 L of ethyl acetate. The solvent wet cake was slurried in 4.0 L of refluxing ethyl acetate for 45 minutes, cooled to 20-25 ° C. for 1 hour, filtered, washed with about 1 L of ethyl acetate, air-dried to give the desired diastereomer salt. 199.6 g (84.6% yield) were obtained. The specific rotation of this mandelic salt
rotation is [α] D = −51.5 ° (CH 2
Cl 2 , c = 0.55) and the melting point is 196-198.
Met.
【0021】12L三つ口フラスコにメカニカルスター
ラー、温度計、pH計を装備した。このフラスコに、精
製マンデル酸塩198.6g(0.35モル)、水3.
97L及び塩化メチレン3.4Lを装入した。この二相
混合物のpHは5.2であり、これを50%水酸化ナト
リウム44mlによってpH13−14に調節した。水
酸化ナトリウム添加中の温度は18℃であった。層を分
離し、水層を塩化メチレン1.7Lによって洗浄した。
有機層を一緒にし、水2Lによって逆洗し、硫酸マグネ
シウムによって乾燥させ、濾過した。濾液を大気中で約
0.5Lに濃縮し、イソプロパノール約0.5Lによっ
て0.5L量及び60℃温度になるように置換した。さ
らにイソプロパノール0.5Lを加え、反応を1.5時
間かけて20−25℃に冷却させた。この冷却期間中
に、白色スラリーが発現し、これを濾過によって単離さ
せ、イソプロパノールによって洗浄し、真空乾燥させ
て、ラセミ出発物質345gから可能な172.5gか
ら、目的鏡像異性体である標題化合物115.5g(6
7.0%収率)を得た。この物質の比旋光度は[α]D
=−22.2゜(CH2 Cl2 ,c=0.50)であ
り、融点は155−157℃であった。A 12 L three-necked flask was equipped with a mechanical stirrer, a thermometer, and a pH meter. In this flask, 198.6 g (0.35 mol) of purified mandelic acid salt, and 3.
97 L and 3.4 L of methylene chloride were charged. The pH of the biphasic mixture was 5.2, which was adjusted to pH 13-14 with 44 ml of 50% sodium hydroxide. The temperature during the addition of sodium hydroxide was 18 ° C. The layers were separated and the aqueous layer was washed with 1.7L of methylene chloride.
The organic layers were combined, backwashed with 2 L of water, dried over magnesium sulfate and filtered. The filtrate was concentrated to about 0.5 L in air and replaced with about 0.5 L of isopropanol to a 0.5 L volume and 60 ° C. temperature. An additional 0.5 L of isopropanol was added and the reaction was allowed to cool to 20-25 C over 1.5 hours. During this cooling period, a white slurry develops, which is isolated by filtration, washed with isopropanol and dried in vacuo to give, from 172.5 g possible from 345 g of the racemic starting material, the title compound which is the desired enantiomer 115.5 g (6
7.0% yield). The specific rotation of this substance is [α] D
= -22.2 ° (CH 2 Cl 2 , c = 0.50) and the melting point was 155 ° -157 ° C.
【0022】実施例4 メカニカルスターラー、温度計、添加ロート及びスチー
ムバスを装備した5L三つ口フラスコに、実施例3の標
題化合物123.3g(0.30モル)とアセトン3.
1Lとを装入した。このスラリーを溶解のために30℃
に加熱してから、再び24℃に冷却した。アセトン25
2mlに溶解したメタンスルホン酸58.6g(0.6
0モル)の溶液を5分間で加えた。この反応は24℃か
ら32℃に温度上昇し、濃厚な白色スラリーになった、
これを周囲温度において2時間攪拌した。反応を大気中
で300−400mlのスラリー量及び60℃の温度に
成るまで濃縮した。このスラリーに、固体物質を溶解す
るメタノール750mlを加えた。この溶液を濾過によ
って“小粒(speck)含まず”にし、150−20
0ml量になるまで大気中で濃縮した。濾過済みイソプ
ロパノール500ml量を加え、反応を150−200
mlになるまで真空濃縮した。さらに濾過済みイソプロ
パノール500ml量を加え、反応を最終量の500m
l及び温度45℃に成るまで真空濃縮した。反応を冷却
すると、結晶化が生じた。このスラリーを周囲温度に冷
却しながら1.5時間攪拌し、次に5℃において45分
間攪拌した。生成物を濾過によって単離し、ケーキを濾
過済み冷イソプロパノール200mlによって2回洗浄
した。45℃において12時間真空乾燥した後に、実施
例3の標題生成物のメタンスルホン酸塩170.7g
(94.4%)が得られた。融点は244.5〜246
℃であり、比旋光度は[α]D =−25.8゜(CH3
OH,c=1.1)であった。 Example 4 In a 5 L three-necked flask equipped with a mechanical stirrer, a thermometer, an addition funnel and a steam bath, 123.3 g (0.30 mol) of the title compound of Example 3 and acetone 3.
1 L was charged. 30 ° C for dissolving this slurry
And cooled again to 24 ° C. Acetone 25
58.6 g of methanesulfonic acid dissolved in 2 ml (0.6 g)
(0 mol) was added over 5 minutes. The reaction increased in temperature from 24 ° C. to 32 ° C., resulting in a thick white slurry.
This was stirred at ambient temperature for 2 hours. The reaction was concentrated to a slurry volume of 300-400 ml and a temperature of 60 ° C. in air. To this slurry was added 750 ml of methanol to dissolve the solid material. The solution was "filtered out" by filtration and 150-20
The mixture was concentrated in the atmosphere until the volume reached 0 ml. 500 ml of filtered isopropanol was added and the reaction was
Concentrated in vacuo to a volume of ml. A further 500 ml of filtered isopropanol was added and the reaction
and concentrated in vacuo to a temperature of 45 ° C. Upon cooling the reaction, crystallization occurred. The slurry was stirred for 1.5 hours while cooling to ambient temperature, then at 5 ° C. for 45 minutes. The product was isolated by filtration and the cake was washed twice with 200 ml of cold filtered isopropanol. After vacuum drying at 45 ° C. for 12 hours, 170.7 g of the methanesulfonate of the title product of Example 3
(94.4%) was obtained. Melting point 244.5-246
° C and the specific rotation is [α] D = -25.8 ° (CH 3
OH, c = 1.1).
───────────────────────────────────────────────────── フロントページの続き (72)発明者 マーティアショー,チャールズ・ダブリ ュー アメリカ合衆国コネチカット州06359, ノース・ストニントン,ノーリッチ−ウ エスタリー・ロード 274 (56)参考文献 特開 昭63−145256(JP,A) 特開 昭63−54342(JP,A) 特開 昭62−192362(JP,A) 特開 昭59−110656(JP,A) 国際公開90/5729(WO,A) ──────────────────────────────────────────────────続 き Continuation of the front page (72) Inventor Martia Shaw, Charles Double, Norwich-Westerly Road, 06359, North Stonington, Connecticut, United States 274 (56) References JP-A-63-145256 (JP, A) JP-A-63-54342 (JP, A) JP-A-62-192362 (JP, A) JP-A-59-110656 (JP, A) International publication 90/5729 (WO, A)
Claims (2)
デル酸と反応させ、式VII 化合物の(−)マンデル酸塩
を精製し、(−)マンデル酸塩を処理し、式VIIの
(−)の化合物を回収することによる前記ラセミ化合物
の分割方法。[Claim 1] The formula: Racemic mixture of the compound - cis shown in (-) is reacted with mandelic acid, of the formula VII the compound (-) was purified mandelate, (-) mandelate processes, of the formula VII - the () A method for resolving the above racemate by recovering the compound.
請求項1の分割方法。2. treating (-) mandelic acid salt with a strong base;
The method according to claim 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US637102 | 1991-01-03 | ||
US07/637,102 US5138060A (en) | 1991-01-03 | 1991-01-03 | Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP92502391A Division JPH05508867A (en) | 1991-01-03 | 1991-12-18 | Methods and intermediates for producing azabicyclo[2,2,2]octane-3-imines |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07316154A JPH07316154A (en) | 1995-12-05 |
JP2703193B2 true JP2703193B2 (en) | 1998-01-26 |
Family
ID=24554545
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4502391A Pending JPH0768244B1 (en) | 1991-01-03 | 1991-12-18 | |
JP92502391A Withdrawn JPH05508867A (en) | 1991-01-03 | 1991-12-18 | Methods and intermediates for producing azabicyclo[2,2,2]octane-3-imines |
JP6322353A Expired - Fee Related JP2583026B2 (en) | 1991-01-03 | 1994-12-26 | Method for producing cis compound of 2-diphenylmethyl-N-phenylmethyl-1-azabicyclo [2,2,2] octane-3-amine compound |
JP6322350A Expired - Fee Related JP2845425B2 (en) | 1991-01-03 | 1994-12-26 | Method for producing intermediate for producing azabicyclo [2,2,2] octane-3-imines |
JP6322355A Expired - Fee Related JP2703193B2 (en) | 1991-01-03 | 1994-12-26 | Method for resolving a racemic mixture of cis compounds of 2-diphenylmethyl-N-[(2-methoxyphenyl) methyl] -1-azabicyclo [2,2,2] octane-3-amine |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4502391A Pending JPH0768244B1 (en) | 1991-01-03 | 1991-12-18 | |
JP92502391A Withdrawn JPH05508867A (en) | 1991-01-03 | 1991-12-18 | Methods and intermediates for producing azabicyclo[2,2,2]octane-3-imines |
JP6322353A Expired - Fee Related JP2583026B2 (en) | 1991-01-03 | 1994-12-26 | Method for producing cis compound of 2-diphenylmethyl-N-phenylmethyl-1-azabicyclo [2,2,2] octane-3-amine compound |
JP6322350A Expired - Fee Related JP2845425B2 (en) | 1991-01-03 | 1994-12-26 | Method for producing intermediate for producing azabicyclo [2,2,2] octane-3-imines |
Country Status (21)
Country | Link |
---|---|
US (1) | US5138060A (en) |
EP (1) | EP0565558B1 (en) |
JP (5) | JPH0768244B1 (en) |
KR (1) | KR970001157B1 (en) |
AT (1) | ATE115580T1 (en) |
AU (1) | AU653380B2 (en) |
CA (2) | CA2098989C (en) |
DE (1) | DE69106003T2 (en) |
DK (1) | DK0565558T3 (en) |
ES (1) | ES2065161T3 (en) |
FI (3) | FI933065A0 (en) |
GR (1) | GR3015021T3 (en) |
HU (1) | HU9301931D0 (en) |
IE (1) | IE65005B1 (en) |
IL (1) | IL100541A0 (en) |
MX (1) | MX9200003A (en) |
NO (1) | NO932431D0 (en) |
NZ (1) | NZ241161A (en) |
PT (1) | PT99970B (en) |
WO (1) | WO1992012152A1 (en) |
ZA (1) | ZA928B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
PL172054B1 (en) * | 1991-06-20 | 1997-07-31 | Pfizer | Method of obtaining novel fluoroalkoxybenzylamine derivatives of nitrogen containing cyclic compounds |
CA2324959C (en) * | 1991-11-12 | 2002-11-12 | Pfizer Limited | Phthalimido compounds as intermediates for producing substance p receptor antagonists |
US5498614A (en) * | 1992-05-18 | 1996-03-12 | Pfizer Inc. | Bridged aza-bicyclic derivatives as substance P antagonist |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5637699A (en) * | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5688804A (en) * | 1992-08-04 | 1997-11-18 | Pfizer Inc. | 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists |
US5387595A (en) * | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
US5518628A (en) * | 1993-11-08 | 1996-05-21 | Shipley Company Inc. | Purification process |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
WO2005045395A2 (en) * | 2003-10-27 | 2005-05-19 | Meyer Donald W | Method of detecting bovine spongiform encephalopathy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3560510A (en) * | 1969-03-05 | 1971-02-02 | Aldrich Chem Co Inc | 2-benzhydrylquinuclidines |
US3993652A (en) * | 1973-07-09 | 1976-11-23 | Air Products And Chemicals, Inc. | Cyclic quaternary hydroxyalkyl phenoxide catalysts for isocyanate reactions |
US4203990A (en) * | 1979-04-30 | 1980-05-20 | G. D. Searle & Co. | Anti-diarrheal 2-substituted quinuclidines |
FR2529548A1 (en) * | 1982-07-02 | 1984-01-06 | Delalande Sa | NOVEL DERIVATIVES OF AMINO-3 QUINUCLIDINE, THEIR PROCESS AND THEIR THERAPEUTIC APPLICATION |
JPS59110656A (en) * | 1982-12-15 | 1984-06-26 | Hiroyuki Nohira | Optical resolution of 1-phenyl-2-(p-tolyl)ethylamine |
DE3604591A1 (en) * | 1986-02-14 | 1987-08-20 | Degussa | METHOD FOR PRODUCING CHIRAL GLYCINE DERIVATIVES |
JPS6354342A (en) * | 1986-08-26 | 1988-03-08 | Daicel Chem Ind Ltd | Optical resolution of (+-)-alpha-ethylbenzylamine |
JPS63145256A (en) * | 1986-12-09 | 1988-06-17 | Nippon Kayaku Co Ltd | Production of optically active homophenylalanine and intermediate therefor |
MX18467A (en) * | 1988-11-23 | 1993-07-01 | Pfizer | THERAPEUTIC AGENTS OF QUINUCLIDINES |
UA26401C2 (en) * | 1991-05-22 | 1999-08-30 | Пфайзер Інк. | SUBSTITUTES OF 3-AMICHOHYCLICIDS |
-
1991
- 1991-01-03 US US07/637,102 patent/US5138060A/en not_active Expired - Lifetime
- 1991-12-18 CA CA002098989A patent/CA2098989C/en not_active Expired - Fee Related
- 1991-12-18 KR KR1019930702007A patent/KR970001157B1/en active IP Right Grant
- 1991-12-18 EP EP92901603A patent/EP0565558B1/en not_active Expired - Lifetime
- 1991-12-18 JP JP4502391A patent/JPH0768244B1/ja active Pending
- 1991-12-18 JP JP92502391A patent/JPH05508867A/en not_active Withdrawn
- 1991-12-18 AU AU91298/91A patent/AU653380B2/en not_active Expired - Fee Related
- 1991-12-18 HU HU9301931A patent/HU9301931D0/en unknown
- 1991-12-18 DK DK92901603.8T patent/DK0565558T3/en active
- 1991-12-18 DE DE69106003T patent/DE69106003T2/en not_active Expired - Fee Related
- 1991-12-18 CA CA002158130A patent/CA2158130C/en not_active Expired - Fee Related
- 1991-12-18 ES ES92901603T patent/ES2065161T3/en not_active Expired - Lifetime
- 1991-12-18 AT AT92901603T patent/ATE115580T1/en not_active IP Right Cessation
- 1991-12-18 WO PCT/US1991/009186 patent/WO1992012152A1/en active Application Filing
- 1991-12-23 NZ NZ241161A patent/NZ241161A/en unknown
- 1991-12-27 IL IL100541A patent/IL100541A0/en unknown
-
1992
- 1992-01-02 ZA ZA928A patent/ZA928B/en unknown
- 1992-01-02 MX MX9200003A patent/MX9200003A/en unknown
- 1992-01-02 PT PT99970A patent/PT99970B/en not_active IP Right Cessation
- 1992-01-02 IE IE920001A patent/IE65005B1/en not_active IP Right Cessation
-
1993
- 1993-07-02 NO NO932431A patent/NO932431D0/en unknown
- 1993-07-02 FI FI933065A patent/FI933065A0/en not_active Application Discontinuation
-
1994
- 1994-12-26 JP JP6322353A patent/JP2583026B2/en not_active Expired - Fee Related
- 1994-12-26 JP JP6322350A patent/JP2845425B2/en not_active Expired - Fee Related
- 1994-12-26 JP JP6322355A patent/JP2703193B2/en not_active Expired - Fee Related
-
1995
- 1995-02-08 GR GR950400264T patent/GR3015021T3/en unknown
-
2000
- 2000-05-10 FI FI20001108A patent/FI20001108A/en not_active Application Discontinuation
- 2000-05-10 FI FI20001109A patent/FI20001109A/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0699199B1 (en) | Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists | |
JP2703193B2 (en) | Method for resolving a racemic mixture of cis compounds of 2-diphenylmethyl-N-[(2-methoxyphenyl) methyl] -1-azabicyclo [2,2,2] octane-3-amine | |
EP0573522B1 (en) | 1-azabicyclo[3.2.2]nonan-3-amine derivatives | |
EP0607164B1 (en) | Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists | |
EP0490962A1 (en) | Antipsychotic 1-cycloalkylpiperidines | |
JP2006501236A (en) | 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives containing fluoro and sulfonylamino as muscarinic receptor antagonists | |
CZ287272B6 (en) | Quaternary basic amide, process of its preparation and pharmaceutical composition in which the amide is comprised | |
JP2002529451A (en) | N-substituted aza rings, methods for their preparation and their use as ORL-1 receptor ligands | |
SK112398A3 (en) | Oxa- and thia-diazole muscarinic receptor antagonists | |
US20080319043A1 (en) | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | |
US5442068A (en) | Process and intermediates for preparing azabicyclo[2.2.2]octan-3-imines | |
NO174669B (en) | Analogous Procedures for the Preparation of Therapeutically Active Benzothiopyranylamines | |
US5216163A (en) | Process for preparing azabicyclo[2.2.2]octan-3-imines | |
EP1633752B1 (en) | Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof | |
CN1104641A (en) | Process for preparing N-tert-butylamides | |
JP2002527423A (en) | Ureidopiperidine derivatives as selective antagonists of the human NK3 receptor | |
JP3888393B2 (en) | Quinolone derivatives | |
JPH05221947A (en) | Production of cyclopropane derivative | |
JPS6341907B2 (en) | ||
JP2000239274A (en) | Production of new naphthyridine derivative | |
WO2002032870A1 (en) | Process of the preparation of 3-substituted-4-aryl piperidine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |